Cantor Fitzgerald Estimates Mesoblast FY2025 Earnings

Mesoblast Limited (NASDAQ:MESO) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Mesoblast in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($0.70) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Mesoblast’s current full-year earnings is ($0.70) per share.

A number of other equities research analysts also recently weighed in on the stock. Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Piper Sandler reaffirmed an “overweight” rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Mesoblast has an average rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Trading Down 7.7 %

NASDAQ MESO opened at $13.68 on Thursday. The firm has a 50-day moving average price of $17.94 and a two-hundred day moving average price of $12.33. Mesoblast has a 12-month low of $2.05 and a 12-month high of $22.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.

Hedge Funds Weigh In On Mesoblast

Several hedge funds and other institutional investors have recently made changes to their positions in MESO. Bank of America Corp DE increased its stake in Mesoblast by 1,503.3% in the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company’s stock valued at $5,756,000 after acquiring an additional 272,595 shares during the last quarter. Oaktree Capital Management LP bought a new position in shares of Mesoblast in the 4th quarter valued at $3,556,000. Strategic Financial Concepts LLC bought a new position in shares of Mesoblast in the 4th quarter valued at $2,744,000. Oaktree Fund Advisors LLC acquired a new position in shares of Mesoblast during the 4th quarter worth $949,000. Finally, XY Capital Ltd bought a new stake in shares of Mesoblast during the 3rd quarter worth $244,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.